Testicular prostheses have been used to deal with anorchia for nearly 80 years. Here, we evaluated a novel testicular prosthesis that can controllably release hormones to maintain physiological levels of testosterone ...Testicular prostheses have been used to deal with anorchia for nearly 80 years. Here, we evaluated a novel testicular prosthesis that can controllably release hormones to maintain physiological levels of testosterone in vivo for a long time. Silastic testicular prostheses with controlled release of testosterone （STPT） with different dosages of testosterone undecanoate （TU） were prepared and implanted into castrated Sprague-Dawley rats. TU oil was applied by oral administration to a separate group of castrated rats. Castrated untreated and sham-operated groups were used as controls. Serum samples from every group were collected to measure the levels of testosterone （T）, follicle-stimulating hormone and luteinizing hormone （LH）. Maximum intracavernous penile pressure （ICPmax） was recorded. The prostates and seminal vesicles were weighed and subjected to histology, and a terminal dexynucleotidyl transferase-mediated UTP nick end labeling （TUNEL） assay was used to evaluate apoptosis. Our results revealed that the weights of these tissues and the levels of T and LH showed significant statistical differences in the oral administration and TU replacement groups compared with the castrated group （P 〈 0.05）. Compared with the sham-operated group, the ICPmax, histology and TUNEL staining for apoptosis, showed no significant differences in the hormone replacement groups implanted with medium and high doses of STPT. Our results suggested that this new STPT could release TU stably through its double semi-permeable membranes with excellent biocompatibility. The study provides a new approach for testosterone replacement therapy.展开更多
该文旨在应用质量源于设计(quality by design,QbD)理念,针对当今中药缓控释制剂研发过程中多种因素影响其最终产品质量的现状,提出开展基于质量源于设计理念的中药缓控释制剂的设计与研发研究。综述了近几年来瞩目的西药与中药缓控释...该文旨在应用质量源于设计(quality by design,QbD)理念,针对当今中药缓控释制剂研发过程中多种因素影响其最终产品质量的现状,提出开展基于质量源于设计理念的中药缓控释制剂的设计与研发研究。综述了近几年来瞩目的西药与中药缓控释制剂的发展,依据中药工艺复杂性等特点,提出基于QbD理念的中药缓控释制剂的设计与研发,应用QbD理念对影响中药缓控释制剂的复杂因素进行梳理,确定影响终产品质量的高风险因素,从过程中着手对高风险因素进行控制,达到质量可控的目的,为中药复杂组分的缓控释制剂提供研究思路,以促进中药缓控释制剂的研发。展开更多
文摘Testicular prostheses have been used to deal with anorchia for nearly 80 years. Here, we evaluated a novel testicular prosthesis that can controllably release hormones to maintain physiological levels of testosterone in vivo for a long time. Silastic testicular prostheses with controlled release of testosterone （STPT） with different dosages of testosterone undecanoate （TU） were prepared and implanted into castrated Sprague-Dawley rats. TU oil was applied by oral administration to a separate group of castrated rats. Castrated untreated and sham-operated groups were used as controls. Serum samples from every group were collected to measure the levels of testosterone （T）, follicle-stimulating hormone and luteinizing hormone （LH）. Maximum intracavernous penile pressure （ICPmax） was recorded. The prostates and seminal vesicles were weighed and subjected to histology, and a terminal dexynucleotidyl transferase-mediated UTP nick end labeling （TUNEL） assay was used to evaluate apoptosis. Our results revealed that the weights of these tissues and the levels of T and LH showed significant statistical differences in the oral administration and TU replacement groups compared with the castrated group （P 〈 0.05）. Compared with the sham-operated group, the ICPmax, histology and TUNEL staining for apoptosis, showed no significant differences in the hormone replacement groups implanted with medium and high doses of STPT. Our results suggested that this new STPT could release TU stably through its double semi-permeable membranes with excellent biocompatibility. The study provides a new approach for testosterone replacement therapy.
文摘该文旨在应用质量源于设计(quality by design,QbD)理念,针对当今中药缓控释制剂研发过程中多种因素影响其最终产品质量的现状,提出开展基于质量源于设计理念的中药缓控释制剂的设计与研发研究。综述了近几年来瞩目的西药与中药缓控释制剂的发展,依据中药工艺复杂性等特点,提出基于QbD理念的中药缓控释制剂的设计与研发,应用QbD理念对影响中药缓控释制剂的复杂因素进行梳理,确定影响终产品质量的高风险因素,从过程中着手对高风险因素进行控制,达到质量可控的目的,为中药复杂组分的缓控释制剂提供研究思路,以促进中药缓控释制剂的研发。
